Skip to main content
PMC home page
JAMA Network logoLink to JAMA Network
. 2019 Jul 10;155(9):1022–1027. doi: 10.1001/jamadermatol.2019.0891

Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease

A Systematic Review and Meta-analysis

Wei-Ti Chen 1,2, Ching-Chi Chi 2,3,✉
PMCID: PMC6625071  PMID: 31290938

Key Points

Question

Is hidradenitis suppurativa associated with inflammatory bowel disease?

Findings

This systematic review and meta-analysis included 5 case-control studies, 2 cross-sectional studies, and 1 cohort study with a total of 93 601 unique participants with hidradenitis suppurativa who had 2.12-fold increased odds for Crohn disease and 1.51-fold increased odds for ulcerative colitis. One cohort study found a 5.6-fold increased risk of inflammatory bowel disease in patients with hidradenitis suppurativa.

Meaning

Gastrointestinal tract symptoms, such as recurrent abdominal pain and chronic diarrhea, should not be overlooked in patients with hidradenitis suppurativa, and consultation with gastroenterologists should be sought.

This systematic review and meta-analysis investigates the associated risk of inflammatory bowel disease in patients with hidradenitis suppurativa.

Abstract

Importance

Hidradenitis suppurativa (HS) and inflammatory bowel disease (IBD) are inflammatory diseases that share common genetic susceptibility and immunologic features. However, the link between HS and IBD has been largely unclear.

Objective

To conduct a meta-analysis to investigate the association between HS and IBD.

Data Sources

A search of the MEDLINE, Cochrane Central Register of Controlled Trials, and Embase databases yielded 397 relevant studies from inception to June 10, 2018. Two additional studies were supplied by one of the investigators.

Study Selection

Case-control, cross-sectional, or cohort studies that examined the odds or risk of IBD in patients with HS were included. No geographic or language limitations were imposed.

Data Extraction and Synthesis

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The Newcastle-Ottawa Scale was used to assess the risk of bias of included studies. Crohn disease and ulcerative colitis were analyzed separately, and a random-effects model meta-analysis was conducted.

Main Outcomes and Measures

The odds ratios (ORs) and hazard ratios (HRs) of IBD, Crohn disease, and ulcerative colitis in association with HS.

Results

Five case-control studies, 2 cross-sectional studies, and 1 cohort study with a total of 93 601 unique participants were included. The meta-analysis of case-control and cross-sectional studies showed significant associations of HS with Crohn disease (pooled OR, 2.12; 95% CI, 1.46-3.08) and ulcerative colitis (pooled OR, 1.51; 95% CI, 1.25-1.82). Two case-control studies found significant association of HS with IBD (ORs, 2.16 [95% CI, 1.40-3.34] and 10.00 [95% CI, 1.94-51.50]). One cohort study found an increased risk of IBD in patients with HS (HR, 5.6; 95% CI not reported; P < .002).

Conclusions and Relevance

The evidence to date supports an association of HS with IBD. These results suggest that consultation with gastroenterologists should be sought when patients with HS present with recurrent abdominal pain, chronic diarrhea, bloody stool, and body weight loss.

Introduction

Hidradenitis suppurativa (HS) or acne inversa is defined as “a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland–bearing areas of the body, most commonly the axillary, inguinal, and anogenital regions” (Dessau definition).1(p619) The etiology is largely unclear, but dysregulated inflammatory response of cytokines, follicular occlusion, obstruction and dilatation of the pilosebaceous unit, and altered microbiota may be involved in the pathogenesis of HS.2,3,4,5

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disease of the intestinal tract. Inflammatory bowel disease consists of 2 predominant types: Crohn disease (CD) and ulcerative colitis (UC).6 Accumulating evidence indicates that genetic susceptibility to dysregulated inflammatory reaction and altered microbiota may play crucial roles in the pathogenesis of IBD.7,8,9

Hidradenitis suppurativa shares common clinical manifestations, genetic susceptibility, and immunologic features with IBD.5,10 Both diseases have similar clinical manifestations in the skin and gut, characterized by sterile abscesses in the perineal and inguinal areas, scarring, and sinus tract formation.1,7,11,12 Hidradenitis suppurativa and IBD have been associated with an increased prevalence of spondyloarthropathy, and both diseases respond well to tumor necrosis factor inhibitors.1,13,14,15,16,17 Moreover, smoking and obesity are known common risk factors for HS and IBD.18,19,20,21

Although some studies have suggested a link between HS and IBD,22,23,24,25 data on the association remain inconsistent and unclear. For example, one recent study26 failed to find a significant association between HS and CD, whereas another study27 did not detect a significant increase of UC in patients with HS. In this study, we aimed to systematically examine the evidence of an association of HS with IBD.

Methods

Eligibility Criteria and Evidence Search

In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline,28 we conducted a meta-analysis of observational studies on the association of HS with IBD. The types of eligible studies included case-control, cross-sectional, and cohort studies.

The MEDLINE, Cochrane Central Register of Controlled Trials, and Embase databases were searched for relevant studies from the respective inception of these databases to June 10, 2018. We did not impose any language or geographic restrictions. Our search strategy is listed in the eTable in the Supplement.

Selection of Studies

Studies that met the following inclusion criteria were included: (1) observational studies examining the association of HS with IBD, including cross-sectional, case-control, or cohort studies; (2) human study participants; and (3) a case group consisting of patients with HS and a control group composed of people without HS. Both authors independently selected relevant studies by scanning the titles and abstracts of search results. The full text of potential studies was obtained and examined for eligibility. Disagreement was resolved by discussion.

Data Extraction and Risk of Bias Assessment

We extracted the following data from the included studies: study design, first author, year of publication, country, and risk estimates, including odds ratios (ORs) and hazard ratios (HRs) with corresponding 95% CIs on the association of HS with IBD. We used the Newcastle-Ottawa Scale to assess the risk of bias of included studies.29

Statistical Analysis

We used Review Manager software, version 5.3 (Nordic Cochrane Centre, Cochrane Collaboration), to conduct meta-analyses when at least 3 studies provided usable data for 1 outcome.30 We calculated a pooled OR with 95% CI for case-control and cross-sectional studies and a pooled HR with 95% CI for cohort studies. The I2 statistic was calculated for examining statistical heterogeneity across the included studies. An I2 of greater than 50% was considered substantial heterogeneity.31 The random-effects model was chosen for meta-analyses because clinical heterogeneity was anticipated.

Results

Characteristics of Included Studies

The PRISMA study flow diagram is shown in Figure 1. After removing duplicates, 397 records were identified by our search. Two additional relevant studies were provided by 1 author (C.-C.C.).26,32 We excluded 375 citations after scanning the titles and abstracts. After examination of the full text, we included 5 case-control studies,26,33,34,35,36 2 cross-sectional studies,27,32 and 1 cohort study37 with a total of 93 601 unique study participants. One study was conducted in Asia,26 and the other 7 were conducted in the West.27,32,33,34,35,36,37 The characteristics of the included case-control studies are shown in Table 1.

Figure 1. PRISMA Study Flowchart.

Figure 1.

Open in a new tab

CENTRAL indicates Cochrane Central Register of Controlled Trials; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Table 1. Characteristics of Included Case-Control and Cross-sectional Studies.

Source (Country) Study Design Group OR (95% CI)
No. of Patients With HS No. of Controls Inflammatory Bowel Disease Crohn Disease Ulcerative Colitis
Shalom et al,27 2016 (Israel) Cross-sectional 3207 6412 NA 2.03 (1.14-3.62) 1.82 (0.81-4.05)
Cices et al,33 2017 (United States) Case-control 1489 (22.7% Male and 77.3% female) 871 398 (38.5% Male and 61.4% female) 2.16 (1.40-3.34) NA NA
Egeberg et al,34 2017 (Denmark) Case-control 7732 4 354 137 NA 2.04 (1.59-2.62) 1.75 (1.44-2.13)
Garg et al,32 2018 (United States) Cross-sectional 52 340 (31.8% Male and 68.2% female) 18 404 260 (44.1% Male and 55.7% female) NA 3.05 (2.87-3.25) NA
Ingram et al,35 2018 (United Kingdom) Case-control 122 187 NA 2.65 (1.89-3.72) NA
Case-control 42 129 NA NA 1.24 (0.79-1.94)
Lee et al,26 2018 (Korea) Case-control 28 516 (61.3% Male and 38.7% female) 142 580 (61.3% Male and 38.7% female) NA 1.23 (0.92-1.63) 1.32 (1.04-1.69)
Tiri et al,36 2018 (Finland) Case-control 153 612 Patients with melanocytic nevi 10.0 (1.94-51.5) NA NA
Open in a new tab

Abbreviations: HS, hidradenitis suppurativa; NA, not available; OR, odds ratio.

Risk of Bias of Included Studies

The risk of bias among included case-control and cohort studies is summarized in Figure 2. No studies were rated with a high risk of bias in any item. As to the adequacy of case definition, 5 studies26,32,33,34,36 were rated with an unclear risk of bias because only codes from the International Classification of Diseases, Eighth Revision, and Ninth Revision, and Tenth Revision were used for identification of cases. Five case-control and cross-sectional studies26,33,34,35,36 and 1 cohort study37 were rated with an unclear risk of bias in the comparability of cases and controls or cohorts because the analyses controlled for age and sex but not body mass index and smoking. As to ascertainment of exposure, 6 case-control and cross-sectional studies26,32,33,34,35,36 and 1 cohort study37 were rated with an unclear risk of bias because only International Classification of Diseases codes were used.

Figure 2. Risk of Bias Among Included Studies.

Figure 2.

Open in a new tab

The Newcastle-Ottawa Scale was used to access the risk of bias. A green dot denotes low risk of bias; yellow, unclear risk of bias.

Association of HS With IBD

Five studies with a combined 91 917 study participants, including 2 cross-sectional studies27,32 and 3 case-control studies,26,34,35 provided data on the association of HS with CD. Substantial statistical heterogeneity was found across these studies (I2 = 92%). As illustrated in Figure 3A, the meta-analysis illustrated a significantly increased odds of CD in patients with HS (pooled OR, 2.12; 95% CI, 1.46-3.08).

Figure 3. Forest Plots of the Association of Hidradenitis Suppurativa (HS) With Crohn Disease and Ulcerative Colitis.

Figure 3.

Open in a new tab

Data were pooled separately by study design using random-effects model; the inverse variance (IV) technique was used for pooling of measures of effects. OR indicates odds ratio; SE, standard error.

Four studies with a combined 39 497 study participants, including 1 cross-sectional study27 and 3 case-control studies,26,34,35 provided data on the association of HS with UC. We found no substantial statistical heterogeneity across these studies (I2 = 28%). As demonstrated in Figure 3B, the meta-analysis showed a significantly increased odds of UC in patients with HS (pooled OR, 1.51; 95% CI, 1.25-1.82).

Two case-control studies33,36 with a combined 1642 study participants provided data on the association of HS with IBD and found significantly increased odds of IBD in subjects with HS (ORs, 2.16 [95% CI, 1.40-3.34] and 10.00 (95% CI, 1.94-51.50]). One cohort study37 with 14 136 study participants found an increased risk of IBD in patients with HS (HR, 5.6; 95% CI not reported; P < .002).

Discussion

To the best of our knowledge, this study is the first meta-analysis to illustrate a significant association of HS with IBD. The evidence from case-control studies indicates that patients with HS had 2.12-fold odds of CD and 1.51-fold odds of UC when compared with controls. Meanwhile, the evidence from 1 cohort study37 reveals that patients with HS had a 5.6-fold HR of IBD when compared with controls.

Hidradenitis suppurativa and IBD share many characteristics, including clinical manifestations, genetic susceptibility, and immunologic features. There are several explanations of the link between HS and IBD. First, genetic susceptibility loci shared by HS and IBD have been found. Certain genes, for example SULT1B1 (OMIM 608436) and SULT1E1 (OMIM 600043), have been associated with HS as well as IBD.5,38,39 Second, emerging studies have shown that HS and IBD are diseases of immune dysregulation. Cytokine abnormalities, such as elevation of interleukin 1 (IL-1), IL-6, IL-17, IL-23, and tumor necrosis factor, are involved in HS and IBD.40,41,42 Third, altered microbiota with dysregulated immune responses may play an important role in HS and IBD.5,43 Microbiota affect the immunologic and physiologic homeostasis of the epithelia of skin and mucosa of gut by activation of toll-like receptors to recognize pathogens and repair damage.44,45,46 However, a variety of environmental factors can alter microbial balance with a resultant decrease in microbial diversity.7 Such alterations of microbiota may cause immune dysregulation and susceptibility to diseases, including HS and IBD.47 Altered microbiota have been found in the lesional and nonlesional skin of patients with HS when compared with healthy control individuals.48 Increasing evidence shows that altered intestinal microbiota may be involved in the pathogenesis of IBD, with decreases in specific Firmicutes species and a concomitant increase in Bacteroidetes species and facultative anaerobes such as Enterobacteriaceae.49 The alterations of microbiota may lead to systemic immune impairment. Such a close interplay between alterations of microbiota, cytokines, and dermatoses has been proposed as the gut-skin axis theory.50

We detected high statistical heterogeneity for the association of HS with CD (I2 = 92%) (Figure 3A). However, no significant statistical heterogeneity was present when we excluded 3 studies26,34,35 that did not control for body mass index and smoking habit (I2 = 47%; P = .17). Therefore, uncontrolled confounding may account for the high statistical heterogeneity detected in Figure 3A.

Limitations

This study has some limitations. First, no studies examined the association between different severity of HS and IBD. Second, most of the included studies were from Western countries (United States and Europe),27,32,33,34,35,36,37 with only 1 from Asia.26 More studies are warranted to confirm whether HS is associated with IBD in Asian or other racial/ethnic groups.

Conclusions

The evidence to date supports an association of HS with IBD. Patients with HS should be informed about the increased risk of IBD. Consultation with gastroenterologists should be sought when patients with HS present with recurrent abdominal pain, chronic diarrhea, bloody stool, and body weight loss.

Supplement 1.

eTable. Search strategy

Click here for additional data file. (91.1KB, pdf)

References

  • 1.Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. doi: 10.1111/jdv.12966 [DOI] [PubMed] [Google Scholar]
  • 2.Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015;173(6):1431-1439. doi: 10.1111/bjd.14075 [DOI] [PubMed] [Google Scholar]
  • 3.Micheletti RG. Hidradenitis suppurativa: current views on epidemiology, pathogenesis, and pathophysiology. Semin Cutan Med Surg. 2014;33(3)(suppl):S48-S50. doi: 10.12788/j.sder.0091 [DOI] [PubMed] [Google Scholar]
  • 4.Guet-Revillet H, Coignard-Biehler H, Jais J-P, et al. Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis. 2014;20(12):1990-1998. doi: 10.3201/eid2012.140064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.van der Zee HH, Horvath B, Jemec GBE, Prens EP. The association between hidradenitis suppurativa and Crohn’s disease: in search of the missing pathogenic link. J Invest Dermatol. 2016;136(9):1747-1748. doi: 10.1016/j.jid.2016.05.102 [DOI] [PubMed] [Google Scholar]
  • 6.Ellinghaus D, Bethune J, Petersen BS, Franke A. The genetics of Crohn’s disease and ulcerative colitis: status quo and beyond. Scand J Gastroenterol. 2015;50(1):13-23. doi: 10.3109/00365521.2014.990507 [DOI] [PubMed] [Google Scholar]
  • 7.Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641-1657. doi: 10.1016/S0140-6736(07)60751-X [DOI] [PubMed] [Google Scholar]
  • 8.Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596-604. doi: 10.1038/ng2032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327-339.e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kamal N, Cohen BL, Buche S, Delaporte E, Colombel JF. Features of patients with Crohn’s disease and hidradenitis suppurativa. Clin Gastroenterol Hepatol. 2016;14(1):71-79. doi: 10.1016/j.cgh.2015.04.180 [DOI] [PubMed] [Google Scholar]
  • 11.Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-561. doi: 10.1016/j.jaad.2008.11.911 [DOI] [PubMed] [Google Scholar]
  • 12.Jemec GB. Clinical practice: hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. doi: 10.1056/NEJMcp1014163 [DOI] [PubMed] [Google Scholar]
  • 13.Richette P, Molto A, Viguier M, et al. Hidradenitis suppurativa associated with spondyloarthritis: results from a multicenter national prospective study. J Rheumatol. 2014;41(3):490-494. doi: 10.3899/jrheum.130977 [DOI] [PubMed] [Google Scholar]
  • 14.Gionchetti P, Calabrese C, Rizzello F. Inflammatory bowel diseases and spondyloarthropathies. J Rheumatol Suppl. 2015;93:21-23. doi: 10.3899/jrheum.150628 [DOI] [PubMed] [Google Scholar]
  • 15.Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor-α in hidradenitis suppurativa patients: is there a basis for treatment with anti–tumour necrosis factor-α agents? Acta Derm Venereol. 2009;89(6):601-603. doi: 10.2340/00015555-0749 [DOI] [PubMed] [Google Scholar]
  • 16.Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel J-F, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716-1730. doi: 10.1053/j.gastro.2015.08.055 [DOI] [PubMed] [Google Scholar]
  • 17.Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev. 2015;(10):CD010081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Nazary M, van der Zee HH, Prens EP, Folkerts G, Boer J. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. Eur J Pharmacol. 2011;672(1-3):1-8. doi: 10.1016/j.ejphar.2011.08.047 [DOI] [PubMed] [Google Scholar]
  • 19.Rosenfeld G, Bressler B. The truth about cigarette smoking and the risk of inflammatory bowel disease. Am J Gastroenterol. 2012;107(9):1407-1408. doi: 10.1038/ajg.2012.190 [DOI] [PubMed] [Google Scholar]
  • 20.Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol. 2009;161(4):831-839. doi: 10.1111/j.1365-2133.2009.09198.x [DOI] [PubMed] [Google Scholar]
  • 21.Miller IM, McAndrew RJ, Hamzavi I. Prevalence, risk factors, and comorbidities of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):7-16. doi: 10.1016/j.det.2015.08.002 [DOI] [PubMed] [Google Scholar]
  • 22.van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? results of a pilot study. Br J Dermatol. 2010;162(1):195-197. doi: 10.1111/j.1365-2133.2009.09430.x [DOI] [PubMed] [Google Scholar]
  • 23.van der Zee HH, de Winter K, van der Woude CJ, Prens EP. The prevalence of hidradenitis suppurativa in 1093 patients with inflammatory bowel disease. Br J Dermatol. 2014;171(3):673-675. doi: 10.1111/bjd.13002 [DOI] [PubMed] [Google Scholar]
  • 24.Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65-70. doi: 10.1016/j.cgh.2015.04.173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Deckers IE, Benhadou F, Koldijk MJ, et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol. 2017;76(1):49-53. doi: 10.1016/j.jaad.2016.08.031 [DOI] [PubMed] [Google Scholar]
  • 26.Lee JH, Kwon HS, Jung HM, Kim GM, Bae JM. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population-based study. J Eur Acad Dermatol Venereol. 2018;32(10):1784-1790. doi: 10.1111/jdv.15071 [DOI] [PubMed] [Google Scholar]
  • 27.Shalom G, Freud T, Ben Yakov G, et al. Hidradenitis suppurativa and Inflammatory bowel disease: a cross-sectional study of 3,207 patients. J Invest Dermatol. 2016;136(8):1716-1718. doi: 10.1016/j.jid.2016.04.003 [DOI] [PubMed] [Google Scholar]
  • 28.Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group . Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wells G, Shea BJ, O’Connell D, Robertson J. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed August 8, 2018.
  • 30.Treadwell JR, Tregear SJ, Reston JT, Turkelson CM. A system for rating the stability and strength of medical evidence. BMC Med Res Methodol. 2006;6:52. doi: 10.1186/1471-2288-6-52 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. http://handbook-5-1.cochrane.org. Published March 2011. Accessed July 10, 2018.
  • 32.Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol. 2018;154(7):814-818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cices A, Ibler E, Majewski S, et al. Hidradenitis suppurativa association at the time of, or subsequent to, diagnosis of inflammatory bowel disease in a large US patient population. J Eur Acad Dermatol Venereol. 2017;31(7):e311-e312. doi: 10.1111/jdv.14097 [DOI] [PubMed] [Google Scholar]
  • 34.Egeberg A, Jemec GBE, Kimball AB, et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol. 2017;137(5):1060-1064. doi: 10.1016/j.jid.2016.11.040 [DOI] [PubMed] [Google Scholar]
  • 35.Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917-924. doi: 10.1111/bjd.16101 [DOI] [PubMed] [Google Scholar]
  • 36.Tiri H, Jokelainen J, Timonen M, Tasanen K, Huilaja L. Somatic and psychiatric comorbidities in hidradenitis suppurativa of childhood and adolescence. J Am Acad Dermatol. 2018;79(3):514-519. doi: 10.1016/j.jaad.2018.02.067 [DOI] [PubMed] [Google Scholar]
  • 37.Panaccione R, Aletaha D, Davis M, Johnson S, Skup M, Garg V. The risk of developing subsequent immune mediated inflammatory diseases: a retrospective matched cohort study. J Crohn Colitis. 2017;11:S437-S438. doi: 10.1093/ecco-jcc/jjx002.822 [DOI] [Google Scholar]
  • 38.Janse IC, Koldijk MJ, Spekhorst LM, et al. Identification of clinical and genetic parameters associated with hidradenitis suppurativa in inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(1):106-113. doi: 10.1097/MIB.0000000000000579 [DOI] [PubMed] [Google Scholar]
  • 39.Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9-16. doi: 10.4161/derm.2.1.12490 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066-2078. doi: 10.1056/NEJMra0804647 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461-1463. doi: 10.1126/science.1135245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Schlapbach C, Hänni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790-798. doi: 10.1016/j.jaad.2010.07.010 [DOI] [PubMed] [Google Scholar]
  • 43.Yang Y, Owyang C, Wu GD. East meets West: the increasing incidence of inflammatory bowel disease in Asia as a paradigm for environmental effects on the pathogenesis of immune-mediated disease. Gastroenterology. 2016;151(6):e1-e5. doi: 10.1053/j.gastro.2016.10.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229-241. doi: 10.1016/j.cell.2004.07.002 [DOI] [PubMed] [Google Scholar]
  • 45.Thrash B, Patel M, Shah KR, Boland CR, Menter A. Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol. 2013;68(2):211.e1-211.e33. [DOI] [PubMed] [Google Scholar]
  • 46.Lai Y, Di Nardo A, Nakatsuji T, et al. Commensal bacteria regulate toll-like receptor 3–dependent inflammation after skin injury. Nat Med. 2009;15(12):1377-1382. doi: 10.1038/nm.2062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Nikoopour E, Singh B. Reciprocity in microbiome and immune system interactions and its implications in disease and health. Inflamm Allergy Drug Targets. 2014;13(2):94-104. doi: 10.2174/1871528113666140330201056 [DOI] [PubMed] [Google Scholar]
  • 48.Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. 2017;153(9):897-905. doi: 10.1001/jamadermatol.2017.0904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Hansen J, Gulati A, Sartor RB. The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Curr Opin Gastroenterol. 2010;26(6):564-571. doi: 10.1097/MOG.0b013e32833f1195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.O’Neill CA, Monteleone G, McLaughlin JT, Paus R. The gut-skin axis in health and disease: a paradigm with therapeutic implications. Bioessays. 2016;38(11):1167-1176. doi: 10.1002/bies.201600008 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplement 1.

eTable. Search strategy

Click here for additional data file. (91.1KB, pdf)

Articles from JAMA Dermatology are provided here courtesy of American Medical Association

RESOURCES